University of Poitiers, IC2MP UMR 7285 CNRS, 4 rue Michel Brunet B27, TSA 51106, 86073 Poitiers cedex 9, France.
J Med Chem. 2023 Aug 24;66(16):10878-10888. doi: 10.1021/acs.jmedchem.3c00551. Epub 2023 Aug 10.
Aptamers have emerged in recent years as alternatives to antibodies or small molecules to interfere with the immune check points by blocking the PD-1/PD-L1 interactions and represent an interesting perspective for immuno-oncology. Aptamers are RNA or DNA nucleotides able to bind to a target with high affinity, with the target ranging from small molecules to proteins and up to cells. Aptamers are identified by the SELEX method that can be modified for specific purposes. The range of applications of aptamers covers therapy as well as new alternative assay technologies similar to ELISA. Aptamers' limited plasma stability can be managed using delivery strategies. The goal of this Perspective is to give an overview of the current development of aptamers targeting the most studied immune checkpoint modulators, PD-1 and PD-L1, and analogous strategies with aptamers for other immuno-related targets.
近年来，适体作为抗体或小分子的替代品出现，通过阻断 PD-1/PD-L1 相互作用来干扰免疫检查点，为免疫肿瘤学提供了一个有趣的视角。适体是 RNA 或 DNA 核苷酸，能够与靶标高亲和力结合，靶标范围从小分子到蛋白质，甚至到细胞。适体通过 SELEX 方法鉴定，可以针对特定目的进行修饰。适体的应用范围涵盖了治疗以及类似于 ELISA 的新型替代检测技术。可以使用递药策略来控制适体的有限血浆稳定性。本综述的目的是概述针对最受研究的免疫检查点调节剂 PD-1 和 PD-L1 的适体的最新发展，以及针对其他免疫相关靶标的适体的类似策略。
